Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327:287 (2 August), doi:10.1136/bmj.327.7409.287
| The first 150 words of the full text of this article appear below. |
EDITORWe agree with Hawton et al that co-proxamol presents a major overdose hazard, their results illustrating the difficulties for licensing authorities in limiting availability of prescription medicines that are only hazardous in overdose.1
Co-proxamol is more likely to result in death; it causes prolongation of the QRS interval in an electrocardiogram in experimental animals and in humans.2 3 This property is usually associated with sodium channel blockade and is a precursor to ventricular arrhythmia. We have shown a significant relation between estimated dextropropoxyphene dose (based on paracetamol concentration) and QRS prolongation in a case of co-proxamol poisoning,4 an effect not seen with other opioid combination products.
Dextropropoxyphene is rapidly absorbed from the gastrointestinal tract, increasing early cardiac risk, with death happening within one hour after ingestion.5 Most patients probably die of co-proxamol poisoning as a result of its combined cardiac (non-opioid) and central nervous system (opioid) effects before hospital
D N Bateman, reader in clinical pharmacology
nick.bateman@luht.scot.nhs.uk
R Afshari, postgraduate fellow
Scottish Poisons Information Bureau, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA